Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/21046| Title: | Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort? | Austin Authors: | John, Thomas ;Chia, Puey Ling | Affiliation: | Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia |
Issue Date: | 1-Apr-2018 | Date: | 2018-01-19 | Publication information: | Clinical Cancer Research 2018; 24(7): 1513-1515 | Abstract: | Cell lines formed from an individual's tumor can be used to predict response to specific therapies and determine genomic predictors. For mesothelioma, where chemotherapy remains the backbone of current therapeutic paradigms, such assays could be used to treat patients with the most effective agents specific to their "chemical profile." Clin Cancer Res; 24(7); 1513-5. ©2018 AACRSee related article by Schunselaar et al., p. 1761. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/21046 | DOI: | 10.1158/1078-0432.CCR-17-3493 | Journal: | Clinical Cancer Research | PubMed URL: | 29351918 | ISSN: | 1078-0432 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.